ESA Data On Survival Benefit In Renal Transplant Grafts Are Insufficient - Medicare Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
The MedCAC review focused narrowly on the benefit of using ESAs - Amgen's Aranesp (darbepoetin alfa) and Centocor Ortho Biotech's Procrit (epoetin alfa) - in transplant graft survival for kidney patients.